BR112020005459A2 - tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3) - Google Patents

tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3) Download PDF

Info

Publication number
BR112020005459A2
BR112020005459A2 BR112020005459-3A BR112020005459A BR112020005459A2 BR 112020005459 A2 BR112020005459 A2 BR 112020005459A2 BR 112020005459 A BR112020005459 A BR 112020005459A BR 112020005459 A2 BR112020005459 A2 BR 112020005459A2
Authority
BR
Brazil
Prior art keywords
polypeptide
composition
fgfr3
composition according
disease
Prior art date
Application number
BR112020005459-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Elvire Gouze
Stéphanie GARCIA
Original Assignee
Pfizer Inc.
Inserm( Institut National De La Santé Et De La Recherche Médicale)
Université Côte d'Azur
Centre National Recherche Scientifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc., Inserm( Institut National De La Santé Et De La Recherche Médicale), Université Côte d'Azur, Centre National Recherche Scientifique filed Critical Pfizer Inc.
Publication of BR112020005459A2 publication Critical patent/BR112020005459A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112020005459-3A 2017-09-20 2018-09-20 tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3) BR112020005459A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762561140P 2017-09-20 2017-09-20
US62/561,140 2017-09-20
PCT/EP2018/075471 WO2019057820A1 (en) 2017-09-20 2018-09-20 ABNORMAL VISCERAL GREASE DEPOSITION TREATMENT USING SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3) POLYPEPTIDES

Publications (1)

Publication Number Publication Date
BR112020005459A2 true BR112020005459A2 (pt) 2020-09-29

Family

ID=63878625

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020005459-3A BR112020005459A2 (pt) 2017-09-20 2018-09-20 tratamento de deposição de gordura visceral anormal usando polipeptídeos de receptor 3 de fator de crescimento de fibroblasto solúvel (sfgfr3)

Country Status (12)

Country Link
US (1) US20200297799A1 (enExample)
EP (1) EP3684394A1 (enExample)
JP (1) JP7335247B2 (enExample)
KR (1) KR20200103621A (enExample)
CN (1) CN111836634A (enExample)
AU (1) AU2018335837A1 (enExample)
BR (1) BR112020005459A2 (enExample)
CA (1) CA3076396A1 (enExample)
IL (1) IL273203A (enExample)
MX (1) MX2020003114A (enExample)
PH (1) PH12020550461A1 (enExample)
WO (1) WO2019057820A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150344855A1 (en) 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
KR102432192B1 (ko) 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도
NL2020176B1 (en) * 2017-12-22 2019-07-02 Van Der Hoeven Horticultural Projects B V Greenhouse
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法
WO2024147597A1 (ko) * 2023-01-03 2024-07-11 서울대학교산학협력단 Fgfr3 발현 또는 활성 억제제의 퇴행성 신경질환 치료 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040109850A1 (en) * 2000-12-18 2004-06-10 Neelam Jaiswal Treatment of bone disorders by modulation of fgfr3
US20150344855A1 (en) * 2013-01-16 2015-12-03 INSERM (Institut National de la Santé et de la Recherche Médicale A Soluble Fibroblast Growth Factor Receptor 3 (FGR3) Polypeptide For Use In The Prevention Or Treatment Of Skeletal Growth Retardation Disorders
RS60593B1 (sr) * 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
CA2972865A1 (en) * 2015-01-07 2016-07-14 Therachon Sas Soluble fgfr3 decoys for treating skeletal growth disorders
KR102432192B1 (ko) * 2016-07-07 2022-08-12 화이자 인코포레이티드 가용성 섬유아세포 성장 인자 수용체 3(sfgfr3) 폴리펩티드 및 이의 용도

Also Published As

Publication number Publication date
EP3684394A1 (en) 2020-07-29
WO2019057820A1 (en) 2019-03-28
AU2018335837A1 (en) 2020-04-23
JP2020534367A (ja) 2020-11-26
IL273203A (en) 2020-04-30
US20200297799A1 (en) 2020-09-24
RU2020113712A3 (enExample) 2022-01-14
JP7335247B2 (ja) 2023-08-29
MX2020003114A (es) 2020-10-20
KR20200103621A (ko) 2020-09-02
CN111836634A (zh) 2020-10-27
CA3076396A1 (en) 2019-03-28
PH12020550461A1 (en) 2021-03-22
RU2020113712A (ru) 2021-10-20

Similar Documents

Publication Publication Date Title
US11697678B2 (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
US20200297799A1 (en) Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
RU2729161C2 (ru) Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
EP2938740B1 (en) Chimeric fgf19 peptides for use in treating bile acid disorders
JP2020172509A (ja) 胆汁酸に関係した障害の治療方法
JP6995069B2 (ja) 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
EP3242888A1 (en) Solube fgfr3 decoys for treating skeletal growth disorders
JP2020015733A (ja) 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
RU2794170C2 (ru) ЛЕЧЕНИЕ АНОМАЛЬНОГО ОТЛОЖЕНИЯ ВИСЦЕРАЛЬНОГО ЖИРА С ИСПОЛЬЗОВАНИЕМ РАСТВОРИМЫХ ПОЛИПЕПТИДОВ РЕЦЕПТОРА ФАКТОРА РОСТА ФИБРОБЛАСТОВ 3 (sFGFR3)
HK40039240A (en) Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
NZ790135A (en) Soluble fibroblast growth factor receptor 3 (SFGFR3) polypeptides and uses thereof
BR122021015030B1 (pt) Uso de uma sequência de peptídeo quimérico
BR112017007816B1 (pt) Composições farmacêuticas e uso das mesmas
BR112015014897B1 (pt) Uso de uma sequência de peptídeo quimérico
HK1215283B (en) Chimeric fgf19 peptides for use in treating bile acid disorders

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: INSERM( INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; UNIVERSITE COTE D'AZUR (FR) ; CENTRE NATIONAL RECHERCHE SCIENTIFIQUE (FR) ; PFIZER INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2846 DE 22-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.